Stock comparison
Haemonetics
Novo Nordisk A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
NVO
Novo Nordisk A/S
Market cap
$199.21B
Sector
Healthcare
Overall winner
Novo Nordisk A/S NVO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | NVO | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 65B | HAE |
| Benjamin Graham | 85A | 61C | HAE |
| Philip Fisher | 60C | 73B | NVO |
| Peter Lynch | 54C | 57C | NVO |
| Joel Greenblatt | 31F | 56C | NVO |
| Charlie Munger | 54D | 76B | NVO |
| Terry Smith | 55D | 72C | NVO |
Side-by-side metrics
| Metric | HAE | NVO |
|---|---|---|
| Market cap | $2.98B | $199.21B |
| P/E (TTM) | 24.8x | 10.4x |
| EV/EBIT | 14.1x | 10.9x |
| ROIC (TTM) | 8.37% | 32.2% |
| Gross margin | 55.74% | 81.85% |
| Net margin | 7.29% | 37.2% |
| Revenue CAGR 5y | 7.65% | 21.72% |
| EPS CAGR 5y | 24.62% | 22.03% |
| Debt / Equity | 1.5x | 0.7x |
| Dividend yield | 0.0% | 4.09% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs 22.03%+11%
NVO leads on
- Dividend yield4.09%vs 0.0%+100%
- Market cap$199.21Bvs $2.98B+99%
- Net margin37.2%vs 7.29%+80%
- ROIC (TTM)32.2%vs 8.37%+74%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.